At the news
? NEUTRALIMPACT 4/10 DEFA14A filed Jun 8, 2026 at 09:25 ET
Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Proposal 4 (equity incentive plan amendment). The board reduced the requested new share increase from 475,000 to 350,000 shares, lowering estimated dilution from ~29.40% to ~24.88%, and is now seeking approval of a 'Revised Seventh Amended Plan' capping total authorized shares at 6,110,000. The matter will be voted on at the June 18, 2026 annual meeting.
- Board cut requested new shares from 475,000 to 350,000 after ISS flagged excessive dilution (estimated 29.40% fully diluted)
- Revised plan would increase total shares reserved from 5,760,000 to 6,110,000, reducing estimated dilution to ~24.88%
- Company noted ~$3.0 million in annualized savings from recent restructuring actions to support disciplined equity usage
- Three-year average burn rate is 3.92% per fiscal years 2023-2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access